

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	. 1	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/797,270 03/10/2004		03/10/2004	Philip E. Hammer	045600/275110	3263
826	7590	09/27/2006		EXAMINER	
ALSTON &			KRUSE, DAVID H		
		I STREET, SUITE 400	ART UNIT	PAPER NUMBER	
CHARLOT	ΓE, NC	28280-4000		1638	
				DATE MAILED: 09/27/2000	6

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary			Application No. Applicant(s)						
			0/797,270	HAMMER ET AL.					
			caminer	Art Unit					
			avid H. Kruse	1638					
Period fo	The MAILING DATE of this commun or Reply	nication appear	s on the cover sheet wi	th the correspondence ad	ldress				
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE N nsions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this coming period for reply is specified above, the maximum some re to reply within the set or extended period for reply reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DATE s of 37 CFR 1.136(a) munication. tatutory period will ap y will, by statute, caus	OF THIS COMMUNIC In no event, however, may a resply and will expire SIX (6) MON see the application to become AB.	CATION. Sply be timely filed THS from the mailing date of this c ANDONED (35 U.S.C. § 133).					
Status									
1)□	Responsive to communication(s) file	ed on							
·			ion is non-final						
′=									
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims			·					
4)🖂	Claim(s) 1-17 is/are pending in the	application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	☐ Claim(s) is/are allowed.								
-									
8) 🛛	Claim(s) 1-17 are subject to restricti	on and/or elec	tion requirement.						
Applicati	on Papers								
9)□	The specification is objected to by th	e Examiner							
	The drawing(s) filed on is/are		ed or b) objected to b	ov the Examiner.					
,—	Applicant may not request that any obje			•					
	Replacement drawing sheet(s) including			, ,	FR 1 121(d)				
11)	The oath or declaration is objected to				• •				
	inder 35 U.S.C. § 119	•							
12) 🗆	Acknowledgment is made of a claim	for foreign price	ority under 35 H.S.C. &	119(a)-(d) or (f)					
_	☐ All b)☐ Some * c)☐ None of:	Tot Totolgii piid	only under 55 0.5.5. g	119(a)-(u) 01 (1).					
۵/۱	1. Certified copies of the priority	documents ha	ve heen received						
	2. Certified copies of the priority			onlication No					
	3. Copies of the certified copies				Stone				
	application from the Internation			received in this ivational	Stage				
* S	see the attached detailed Office action		• • •	eceived					
	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		Johnson dopiod flot i						
Attachment	` '								
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (P	PTO-9481		ummary (PTO-413) //Mail Date					
	nation Disclosure Statement(s) (PTO/SB/08)	, 0-070)		formal Patent Application					
	No(s)/Mail Date		6) Other:						

Application/Control Number: 10/797,270 Page 2

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-7 and 9-15, drawn to a method of making an herbicide resistant plant cell transformed with construct comprising a nucleotide sequence encoding a decarboxylase, classified in class 435, subclass 468, for example.
- II. Claims 1-6, 8, 16 and 17, drawn to a method of making an herbicide resistant bacterial cell transformed with construct comprising a nucleotide sequence encoding a decarboxylase, classified in class 435, subclass 471, for example.

Generic claims will be examined to the extent that they read on the elected invention. Note claims 1-6 in Groups I and II.

- 2. The inventions are distinct, each from the other because of the following reasons: Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions the method of Group I and Group II have different starting materials, i.e. plant cells or bacterial cells, and thus are distinct methods.
- 3. Applicant is required to elect one decarboxylase to examine with the elected invention because each decarboxylase would have distinct substrates and confer resistance to distinct herbicides, and thus would be functionally distinct inventions. In

species.

addition, Applicant is required to elect one nucleic acid sequence and one encoded amino acid sequence to be examined in conjunction with the elected group of claims. The Patent and Trademark Office recently published its policy for the examination of patent applications that claim large numbers of nucleotide sequences in the Official Gazette, 1192 O.G. 68 (November 19, 1996). Nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. § 121. Absent evidence to the contrary, each such nucleotide is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. § 121 and 37 CFR § 1.141. In establishing the new policy, the Commissioner has partially waived the requirements of 37 CFR § 1.141et seq. and permits a reasonable number of such nucleotide sequences to be claimed in a single application. It has been determined that normally ten sequences constitute a reasonable number for examination purposes. The Official Gazette Notice of November 19, 1996 is one that permits the examiner to waive restriction to no more than one invention. Since 1996, databases and resource allocations at the PTO have changed and the examination of 10 sequences on the merits in the instant application would present a burden on PTO resources. Additionally, it is noted that one nucleotide and one amino acid sequence is within the O.G. notice range of "up to ten" sequences. This election is not to be construed as an election of

Page 3

Application/Control Number: 10/797,270 Page 4

Art Unit: 1638

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter, and because the search required for one of the groups is not required for another, restriction for examination purposes as indicated is proper.

- 5. Applicant is advised that the reply to this requirement to be complete within one month (not less than 30 days) must include an election of the invention to be examined even though the requirement be traversed (37 CFR § 1.143).
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR § 1.48(b) and by the fee required under 37 CFR § 1.17(i).

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to David H. Kruse, Ph.D. whose telephone number is (571) 272-0799. The examiner can normally be reached on Monday to Friday from 8:00 a.m. to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached at (571) 272-0975. The fax telephone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group Receptionist whose telephone number is (571) 272-0547.

DAVID H. KRUSE, PH.D. PRIMARY EXAMINER

David H. Kruse, Ph.D. 12 September 2006

8. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.